This is a heavily interactive web application, and JavaScript is required. Simple HTML interfaces are possible, but that is not what this is.
Post
Newsramp
newsramp.com
did:plc:xlsujlrwr5xpfxgaf4pixhri
GeoVax (GOVX) completes key manufacturing, regulatory, and preclinical milestones for its GEO-MVA mpox/smallpox vaccine, targeting Phase 3 immune-bridging study launch in Q4 2026 with results expected mid-2027. #Biotech #Vaccines
2026-08-06T14:00:04.465Z